in

U.S. FDA accepts Biogen’s marketing application for its Alzheimer’s drug

Biogen and Japan’s Eisai said on Friday the U.S. Food and Drug Administration has accepted their marketing application for experimental Alzheimer’s disease treatment aducanumab.

Source: Business - cnbc.com

Stocks making the biggest moves in the premarket: TripAdvisor, T-Mobile US, FedEx, Uber & more

State Department lifts international ‘do not travel’ advisory, but hurdles remain